Lakefront Biotherapeutics (LKFT) Cash from Investing Activities (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash from Investing Activities for 11 consecutive years, with $70.0 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities fell 27.43% year-over-year to $70.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $326.8 million (up 10.82% YoY) and the FY2025 annual result came in at $328.7 million, up 30.92% from the prior year.
• Cash from Investing Activities fell to $70.0 million in Q1 2026 per LKFT's latest filing, from $82.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for LKFT reached as high as $96.4 million in Q1 2025 and fell as low as -$1.1 billion in Q1 2022.
• A 5-year average of -$102.5 million and a median of $70.0 million in 2026 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 321.89% — and 2026, when it dropped 27.43%.
• Year by year, Cash from Investing Activities stood at $20.6 million in 2022, then soared by 321.89% to $86.9 million in 2023, then dropped by 10.53% to $77.8 million in 2024, then climbed by 6.24% to $82.6 million in 2025, then declined by 15.32% to $70.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $70.0 million, $82.6 million, and $96.4 million for Q1 2026, Q4 2025, and Q1 2025 respectively.